ALKS vs EXAS · P/E 14, rev $1.56B vs rev $2.76B
Alkermes Plc (ALKS) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the ALKS and EXAS stock pages for the full models.
Not investment advice.